Search for: "Boehringer Ingelheim International GMBH" Results 1 - 20 of 29
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Apr 2020, 9:57 pm by Patent Docs
Plaintiffs-Appellants Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Corp.; and Boehringer Ingelheim... [read post]
8 May 2016, 9:59 pm by Patent Docs
KG; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Aug 2009, 4:54 pm
KG; Boehringer Ingelheim International GmbH Declaratory judgment of invalidity, unenforceability, and non-infringement of U.S. [read post]
2 Jun 2018, 5:55 am by Adrian Chew
A full summary of this case has been published on Kluwer IP Law More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post United Kingdom: Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, Court of Appeal of England and Wales, Civil Division,… [read post]
9 Jul 2018, 10:00 pm by Shane O'Brien
More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post Ireland: Re Boehringer Ingelheim Pharma GmbH & Co. [read post]
2 May 2013, 10:30 am by Amanda Greenburg
On March 26, 2013, Plaintiff Lisa Mulhall filed a claim in the Illinois Southern District Court against the manufacturers of Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH, for causing her mother’s death. [read post]
21 Mar 2014, 7:59 am by Robert Kraft
Bloomberg News reported Boehringer Ingelheim GmbH failed to reveal “a data analysis to U.S. regulators that” suggested the blood-thinner Pradaxa “may have caused more fatal bleeding after it was cleared for sale than the drug did in a study used to win approval,” citing unsealed court filings. [read post]
13 Feb 2014, 6:00 am by LTA-Editor
District Court Judge David Herndon from the Southern District of Illinois imposed close to $1 million in punitive damages on defendants Boehringer Ingelheim International GMBH (“BII”) and Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
27 Jun 2018, 1:16 am by Jani Ihalainen
The Court concluded that their actions therefore would not amount to repackaging as set out in Boehringer Ingelheim. [read post]
27 Jun 2018, 1:16 am by Jani Ihalainen
The Court concluded that their actions therefore would not amount to repackaging as set out in Boehringer Ingelheim. [read post]
13 Nov 2019, 9:15 am by Aziz Burgy
Boehringer Ingelheim International GMBH, IPR2016-01563, Paper 16 (Feb. 3, 2017), that a relied-upon Glucophage label had no source identifying information or indicia of when it became publicly available and the declaration attesting to its publication was not based on personal knowledge, but was merely conclusory. [read post]
28 Jan 2014, 11:53 am
  In re Petition of Boehringer Ingelheim Pharmaceuticals, Inc., and Boehringer Ingelheim Int’l. [read post]
4 Feb 2009, 10:01 am
Of course, the skills of a well-trained patent attorney come in very handy in getting this kind of application over the high bar at the EPO.The latter approach is what at least one party took in the recent case of   Laboratorios Almirall SA v Boehringer Ingelheim International GmbH [2009] EWHC 102 (Pat), the judgment of which was issued last week by His Honour Judge Fysh QC. [read post]
25 Aug 2009, 1:30 pm
Boehringer Ingelheim International GmbH v Commissioner of Patents [2001] FCA 647 and Prejay Holdings Ltd v Commissioner of Patents [2003] FCAFC 77 applied. [read post]
26 Apr 2007, 9:28 am
The two big trade mark decisions of the European Court of Justice today have been a little overshadowed by the festivities for World Intellectual Property Day, but the IPKat took just enough time off from his ecstatic celebrations to check the Curia website and see what the ECJ had in store for him.Right: objection to the repackaging of pharma products has led to some grey goods traders taking extreme measures to avoid trade mark infringment litigationCase C-348/04, Boehringer… [read post]
16 Mar 2015, 3:10 am
CJEU rules in telmisartan SPC disputeAfter his own earlier post on the CJEU’s decision in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
1 May 2010, 11:00 am by Oliver G. Randl
The present decision deals with the refusal of an application on the ground of unallowable double patenting. [read post]
31 Jan 2011, 8:10 am by Stefanie Levine
Terminal Disclaimers and Section 121 Boehringer Ingelheim International GmbH v. [read post]